Associate Director, Cell Therapy Account Management - East Los Angeles, CA
Gilead Sciences
Summary
The Associate Director Cellular Therapy Account Manager (CTAM) has primary responsibility for developing the relationship with Kite's Authorized Treatment Centers (ATCs) and serves as the ATC's primary point of contact with Kite. In this role, the CTAM is responsible for driving appropriate utilization of Kite's CAR T therapies within the account and ensuring the delivery of a seamless customer experience.
Job description
Territory: East Los Angeles, CA. This is a field-based position based in East Los Angeles, CA. Candidates should reside within 20 miles of the geography.
Key Responsibilities
Account Ownership & Demand Generation
- Own overall performance, strategy, and execution for assigned ATCs and associated referral networks
- Drive appropriate patient identification, referral, and therapy adoption through compliant education and engagement
- Differentiate Kite CAR T therapies versus alternative options using approved messaging
- Develop and execute comprehensive account and territory plans aligned with regional and national priorities
- Deliver against defined sales goals, KPIs, and growth objectives
Stakeholder Engagement & Relationship Leadership
- Build trusted relationships with treating physicians, referrers, transplant teams, administrators, and key influencers
- Navigate complex academic and integrated delivery networks to align priorities and remove barriers to care
- Lead engagement across multiple stakeholders to support class and brand growth
- Represent Kite at scientific congresses, speaker programs, and peer to peer educational forums
Patient Access & Cell Therapy Coordination
- Identify, map, and optimize patient referral pathways within hematology and oncology networks
- Partner with cross functional peers to support patient access, reimbursement education, and logistical coordination
- Support ATC readiness and comfort with CAR T processes to enable demand generation
Cross Functional Leadership & Collaboration
- Act as the "quarterback" across Medical, Market Access, Operations, and ATC Onboarding teams
- Provide timely insights on account trends, competitive dynamics, and market opportunities
- Influence resource prioritization to address account specific needs and growth opportunities
- Ensure all activities are executed in compliance with company policies
Basic Qualifications
- BA/BS and 10 years of experience OR MA/MS and 8 years of experience OR PhD and 2 years of experience
Preferred Qualifications
- MBA
- Demonstrated record of successful oncology account management within an academic setting
- Deep clinical expertise in hematology / oncology disease and understanding of treatment landscape (5+ years of experience)
- Demonstrated record of successful account management in large accounts (direct or indirect line leadership experience)
- Strong clinical understanding of cell therapy and ability to manage complex treatment logistics
- Direct line leadership experience
Requirements
- BA/BS and 10 years of experience OR MA/MS and 8 years of experience OR PhD and 2 years of experience
- Demonstrated record of successful oncology account management within an academic setting
- Deep clinical expertise in hematology / oncology disease and understanding of treatment landscape (5+ years of experience)
- Demonstrated record of successful account management in large accounts
- Strong clinical understanding of cell therapy and ability to manage complex treatment logistics
- Direct line leadership experience
- Candidates should reside within 20 miles of East Los Angeles, CA
Benefits
- Paid Time Off
- Discretionary Annual Bonus
- Stock-Based Long-Term Incentives
- Medical, Dental & Vision
- Life Insurance
Company overview
Gilead Sciences, Inc. is a leading American biopharmaceutical company headquartered in Foster City, California, that specializes in researching, developing, and commercializing innovative medicines for life-threatening diseases. Founded in 1987, Gilead has grown into a global healthcare leader with approximately 17,600 employees worldwide. The company's primary therapeutic focus areas include HIV/AIDS, viral hepatitis (hepatitis B and C), oncology, inflammation, and respiratory diseases. Gilead is renowned for its groundbreaking antiviral therapies, including Sovaldi and Harvoni for hepatitis C, and its comprehensive portfolio of HIV treatments such as Truvada, Atripla, and Biktarvy. The company also developed Veklury (remdesivir) for COVID-19 treatment. Gilead operates as a publicly traded company on the NASDAQ (GILD) and is a component of both the Nasdaq-100 and S&P 100 indices. Through strategic acquisitions like Kite Pharma and Immunomedics, Gilead has expanded into cell therapy and oncology, demonstrating its commitment to advancing medical science and improving patient outcomes globally.